Compare SLE & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLE | CANF |
|---|---|---|
| Founded | 2014 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1M | 2.9M |
| IPO Year | 2019 | N/A |
| Metric | SLE | CANF |
|---|---|---|
| Price | $0.61 | $0.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $5.00 | $3.25 |
| AVG Volume (30 Days) | 291.0K | ★ 10.1M |
| Earning Date | 11-13-2025 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,568,000.00 | $560,000.00 |
| Revenue This Year | N/A | $461.72 |
| Revenue Next Year | $29.55 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.53 | $0.17 |
| 52 Week High | $33.20 | $2.33 |
| Indicator | SLE | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 35.14 | 35.71 |
| Support Level | $0.53 | $0.17 |
| Resistance Level | $0.64 | $0.27 |
| Average True Range (ATR) | 0.07 | 0.03 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 22.17 | 21.60 |
Super League Enterprise Inc is the rocket ship to the metaverse. It is a creator and publisher of content experiences and media solutions across the globe's immersive platforms. Its solutions provide incomparable access to massive audiences that gather in immersive digital spaces to socialize, play, explore, collaborate, shop, learn, and create. The company offers a complete range of development, distribution, monetization, and optimization capabilities designed to engage users through dynamic, energized programs. It generates revenue from advertising, including immersive game world and experience publishing and in-game media products, direct-to-consumer offers, including in-game items, e-commerce, game passes and ticketing and digital collectibles, and content and technology.
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).